CXCL9 and glioma: Specifically, loss of Notch signaling (mainly Notch1, Notch2, RBP-J, and Hey1) in glioma cells suppressed the expression of MHC-I and cytokines [e.g., C-X-C motif chemokine ligand 9 (CXCL9) and IL-15], reduced the recruitment of anti-tumor immune cells (e.g., CD8+ T cells), but favored the infiltration of microglia and pro-tumor TAMs [142].